Protara Therapeutics, Inc. (TARA)
USD 5.16
(-8.19%)
USD 5.16
(-8.19%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -37.55 Million | -26.45 Million | -34.5 Million | -23.4 Million | -15.64 Million | -23.23 Million |
| Net Income | -40.42 Million | -65.95 Million | -47.25 Million | -33.97 Million | -14.99 Million | -20.72 Million |
| Depreciation & Amortization | 341 Thousand | 248 Thousand | 117 Thousand | 196 Thousand | 279 Thousand | 115 Thousand |
| Deferred income taxes | -848 Thousand | - | - | -9.94 Million | - | - |
| Stock-based compensation | 6.09 Million | 6.68 Million | 10.36 Million | 9.74 Million | 943 Thousand | 3.42 Million |
| Change in working capital | -4.13 Million | 539 Thousand | 534 Thousand | 629 Thousand | -1.87 Million | -5.97 Million |
| Other non-cash items | 1.41 Million | 32.02 Million | 1.73 Million | 9.94 Million | -4000.00 | -76 Thousand |
| Investing Cash Flow | 53.1 Million | 14.95 Million | -98.19 Million | 2.83 Million | 2.48 Million | 18.42 Million |
| Investments in PPE | -45 Thousand | -120 Thousand | -596 Thousand | -884 Thousand | -16 Thousand | -119 Thousand |
| Acquisitions | - | -15.07 Thousand | 97.59 Thousand | 3.71 Million | - | - |
| Investment purchases | -12.18 Million | -43.55 Million | -124.74 Million | - | - | -15.44 Million |
| Sales/Maturities of investments | 65.33 Million | 58.62 Million | 27.15 Million | - | 2.5 Million | 33.98 Million |
| Other Investing Activities | 1.00 | 15.07 Thousand | -97.59 Thousand | 3.71 Million | - | - |
| Financing Cash Flow | -91 Thousand | -90 Thousand | -228 Thousand | 189.4 Million | 500 Thousand | 2.98 Million |
| Debt repayment | - | - | - | -1.66 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -91 Thousand | -90 Thousand | -228 Thousand | - | - | - |
| Common Stock Issuance | - | - | - | 87.85 Million | 500 Thousand | 2.85 Million |
| Other Financing Activities | -91 Thousand | -90 Thousand | -228 Thousand | 103.22 Million | 500.00 | 132 Thousand |
| Accounts receivables | - | - | - | - | 17 Thousand | 49 Thousand |
| Accounts payables | 848 Thousand | 631 Thousand | 40 Thousand | 198 Thousand | -2.49 Million | -6.16 Million |
| Inventory | - | - | - | - | -17 Thousand | - |
| Other working capital | -4.98 Million | -92 Thousand | 494 Thousand | 431 Thousand | 625 Thousand | 190 Thousand |
| Cash at beginning of period | 24.12 Million | 36.46 Million | 169.39 Million | 564 Thousand | 19.39 Million | 21.19 Million |
| Cash at end of period | 39.58 Million | 24.87 Million | 36.46 Million | 169.39 Million | 6.23 Million | 19.39 Million |
| Capital Expenditure | -45 Thousand | -120 Thousand | -596 Thousand | -884 Thousand | -16 Thousand | -119 Thousand |
| Effect of forex changes on cash | - | - | - | - | -500 Thousand | 22 Thousand |
| Net cash flow / Change in cash | 15.45 Million | -11.59 Million | -132.92 Million | 168.82 Million | -13.16 Million | -1.79 Million |
| Free Cash Flow | -37.6 Million | -26.57 Million | -35.09 Million | -24.29 Million | -15.66 Million | -23.35 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.51 Million | -11.09 Million | -10.22 Million | -40.42 Million | -9.86 Million | -11.29 Million |
| Depreciation & Amortization | 83 Thousand | 83 Thousand | 107 Thousand | 341 Thousand | 107 Thousand | 78 Thousand |
| Deferred income taxes | - | - | -1.73 Million | -848 Thousand | -1 Million | -133 Thousand |
| Stock-based compensation | 1.06 Million | 1.22 Million | 1.45 Million | 6.09 Million | 1.44 Million | 1.61 Million |
| Change in working capital | 436 Thousand | -771 Thousand | -227 Thousand | -4.13 Million | 1.87 Million | -19 Thousand |
| Other non-cash items | 1.06 Million | 3.03 Million | 1.92 Million | 1.41 Million | 882 Thousand | 342 Thousand |
| Investing Cash Flow | 2.94 Million | 23.1 Million | 14.51 Million | 53.1 Million | 6.37 Million | 22.35 Million |
| Investments in PPE | -55 Thousand | - | - | -45 Thousand | -37 Thousand | -2000.00 |
| Acquisitions | - | - | 9866.00 | - | - | - |
| Investment purchases | - | - | - | -12.18 Million | - | - |
| Sales/Maturities of investments | 3 Million | 23.1 Million | 14.51 Million | 65.33 Million | 6.41 Million | 22.35 Million |
| Other Investing Activities | 3 Million | 23.1 Thousand | -14.51 Million | 1.00 | 6415.00 | 22.35 Thousand |
| Financing Cash Flow | 42.09 Million | -76 Thousand | 4000.00 | -91 Thousand | -27 Thousand | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -11 Thousand | - | - | - | -2000.00 | - |
| Common Stock Repurchased | 76 Thousand | -76 Thousand | 91 Thousand | -91 Thousand | -27 Thousand | - |
| Common Stock Issuance | 42.09 Million | - | - | - | - | - |
| Other Financing Activities | -83 Thousand | -76 Thousand | -87 Thousand | -91 Thousand | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 413 Thousand | -1.46 Million | -70 Thousand | 848 Thousand | 652 Thousand | -2.22 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 23 Thousand | 691 Thousand | -157 Thousand | -4.98 Million | 1.22 Million | 2.21 Million |
| Cash at beginning of period | 52.23 Million | 39.58 Million | 33.76 Million | 24.12 Million | 33.97 Million | 21.78 Million |
| Cash at end of period | 89.58 Million | 52.23 Million | 39.58 Million | 39.58 Million | 33.76 Million | 34.72 Million |
| Capital Expenditure | -55 Thousand | - | - | -45 Thousand | -37 Thousand | -2000.00 |
| Effect of forex changes on cash | - | - | 12.6 Million | - | 209.79 Thousand | -12.81 Million |
| Net cash flow / Change in cash | 37.35 Million | 12.64 Million | 5.81 Million | 15.45 Million | -210 Thousand | 12.94 Million |
| Free Cash Flow | -7.74 Million | -10.37 Million | -8.7 Million | -37.6 Million | -6.59 Million | -9.41 Million |
SPDV
688255
SNANF
GCI
002132
600606